IQV Add to watchlist $207.83 +0.28 (+0.13%) Last updated: Jul 15, 2026 04:34
52-Week Range
$207.83
$154.50 $207.83 $247.05

Fundamentals Overview

IQVIA Holdings Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 25.5 PEG 6.66 P/B 5.63 P/S 2.09

Intrinsic value (DCF)

+19.8% upside vs price

Profitability

Net margin 8.3%

Risk (Beta)

1.2 — in line vol

Earnings & growth

EPS $8.16 Rev -4.9% Profit -46.7% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 77% confidence Risk: Moderate Volatility — Beta 1.2. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +19.8% upside vs price · Analyst grade: B+ · Sentiment improving (5 upgrades) · 3M vs S&P 500: +11.3% · 3M vs Healthcare sector: +13.9%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$34.69B
P/E (TTM)
25.48
EPS (TTM)
$8.16
Dividend Yield
N/A
52-Week Range
$154.50 - $247.05
Volume vs Avg
N/A
Beta
1.2

About

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of clo...
Sector: Healthcare
Headquarters: US
Employees: 93,000
IPO Date: May 2013
Website: www.iqvia.com
Beta: 1.2 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 13, Equal Weight: 3, Hold: 2, Neutral: 2, Outperform: 6, Overweight: 4.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $248.93; current price is $207.83. That’s a +19.8% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 25.48
DCF value (model) $248.93 (19.8% upside)
PEG (TTM) 6.66
P/B (TTM) 5.63
P/S (TTM) 2.09
P/FCF (TTM) 13.63
Liquidity & enterprise
Current Ratio (TTM) 0.75
Quick Ratio (TTM) 0.75
Cash Ratio (TTM) 0.23
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 8.33%
Gross margin (TTM) 26.11%
Operating margin (TTM) 13.86%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for IQV.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 13Equal Weight 3Hold 2Neutral 2Outperform 6Overweight 4
5 upgrades, 2 downgrades
Price Target Consensus
Current $207.83
Median $240.00
Consensus $228.09
Low consensus $185.00
High consensus $250.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Mizuho maintain Outperform Outperform 2026-07-13
Baird maintain Outperform Outperform 2026-07-01
Morgan Stanley downgrade Overweight Equal Weight 2026-06-17
Evercore ISI Group maintain Outperform Outperform 2026-04-08
TD Cowen upgrade Hold Buy 2026-03-09
Barclays upgrade Equal Weight Overweight 2026-03-06
Truist Securities maintain Buy Buy 2026-02-19
Jefferies maintain Buy Buy 2026-02-06
UBS maintain Buy Buy 2026-02-06
JP Morgan maintain Overweight Overweight 2026-02-06
Stifel maintain Buy Buy 2026-02-06
Barclays maintain Equal Weight Equal Weight 2026-02-06
Citigroup maintain Neutral Neutral 2026-02-06
TD Cowen maintain Hold Hold 2026-01-22
UBS maintain Buy Buy 2026-01-08
Truist Securities maintain Buy Buy 2026-01-08
Morgan Stanley maintain Overweight Overweight 2025-12-02
TD Cowen downgrade Buy Hold 2025-11-03
Truist Securities maintain Buy Buy 2025-10-29
Stifel maintain Buy Buy 2025-10-29
Citigroup maintain Neutral Neutral 2025-10-29
Baird upgrade Neutral Outperform 2025-10-29
UBS maintain Buy Buy 2025-10-29
JP Morgan maintain Overweight Overweight 2025-10-29
HSBC upgrade Hold Buy 2025-10-09
Evercore ISI Group maintain Outperform Outperform 2025-10-08
Barclays maintain Equal Weight Equal Weight 2025-10-02
Jefferies upgrade Hold Buy 2025-09-09
Mizuho maintain Outperform Outperform 2025-07-25
Truist Securities maintain Buy Buy 2025-07-23